Table 1 Participant characteristics by Cohorts (n = 400)
|  | Cohort 1 n = 200 | Cohort 2 n = 200 | Total n = 400 | p-value |
|---|---|---|---|---|
Group size | 200 (50%) | 200 (50%) | 400 (100%) | Â |
Gender (male) | 117 (58%) | 119 (60%) | 236 (59%) | 0.839 |
Age (years)a | 38 (28–48) | 35 (28–44) | 36 (28–46) | 0.059b |
Ethnicity | ||||
- Australian | 152 (76%) | 137 (68%) | 289 (72%) | 0.056 |
- Asian | 20 (10%) | 14 (7%) | 34 (8%) | |
- Pacific Islander | 13 (6%) | 23 (12%) | 36 (9%) | |
- Other | 15 (8%) | 26 (13%) | 41 (10%) | |
Admissions (last 12Â months) | ||||
- One or two | 157 (78%) | 165 (82%) | 322 (80%) | 0.582 |
- Three or four | 27 (14%) | 21 (10%) | 48 (12%) | |
- Five or more | 16 (8%) | 14 (7%) | 30 (8%) | |
Hospital duration (days)a | 8 (4–17) | 10 (5–22) | 9 (5–19) | 0.317c |
Primary diagnosis | ||||
- Schizophrenia | 72 (36%) | 76 (38%) | 148 (37%) | 0.946 |
- Bipolar disorder | 27 (14%) | 26 (13%) | 53 (13%) | |
- Other psychotic disorder | 30 (15%) | 32 (16%) | 62 (16%) | |
- Other | 71 (36%) | 66 (33%) | 137 (34%) | |
Comorbid substance use disorder | 77 (38%) | 46 (23%) | 123 (31%) | 0.001 |
Involuntary treatment | 77 (38%) | 84 (42%) | 161 (40%) | 0.475 |
Previous clozapine trial | 23 (12%) | 20 (10%) | 43 (11%) | 0.628 |